19 June 2013
Keywords: dendreon, posts, strong, results, provenge, combination, therapy
Article | 07 March 2005
US cancer specialist biotechnology group Dendreon has revealed strong results from a Phase II study of its experimental vaccine Provenge. ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
7 March 2005
© 2013 thepharmaletter.com